Tofacitinib Citrate
Brand name: Xeljanz Xr
Rank #59 of 500 drugs by total cost
$294.4M
Total Cost
49,478
Total Claims
$294.4M
Total Cost
1,925
Prescribers
$5,950
Cost per Claim
948
Beneficiaries
53,123
30-Day Fills
$153K
Avg Cost/Provider
26
Avg Claims/Provider
About Tofacitinib Citrate
Tofacitinib Citrate (sold as Xeljanz Xr) was prescribed 49,478 times by 1,925 Medicare Part D providers in 2023, costing the program $294.4M. At $5,950 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 56 | Albuterol Sulfate (Albuterol Sulfate Hfa) | $312.2M | 7,904,120 |
| 57 | Rifaximin (Xifaxan) | $310.0M | 111,328 |
| 58 | Sitagliptin Phos/Metformin Hcl (Janumet) | $302.2M | 329,315 |
| 59 | Tofacitinib Citrate (Xeljanz Xr) | $294.4M | 49,478 |
| 60 | Umeclidinium Brm/Vilanterol Tr (Anoro Ellipta) | $294.3M | 480,651 |
| 61 | Gabapentin (Gabapentin) | $291.0M | 15,142,335 |
| 62 | Cabozantinib S-Malate (Cabometyx) | $287.3M | 11,285 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology